ImmunityBio, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ImmunityBio, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.29M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $14.75M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $622.0K | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $240.0K | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $934.0K | Mar 19, 2024 |
| FY2023 | Mar 31, 2021 | $139.0K | Mar 19, 2024 |
| FY2020 | Dec 31, 2020 | $21.0K | Mar 4, 2021 |
| FY2020 | Sep 30, 2020 | $68.0K | Mar 4, 2021 |
| FY2020 | Jun 30, 2020 | $1.0K | Mar 4, 2021 |
| FY2020 | Mar 31, 2020 | $21.0K | Mar 4, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.29M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $14.75M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $622.0K | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $240.0K | Mar 3, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($351.40M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($413.56M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | ($583.20M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | ($416.57M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($346.79M) | Mar 19, 2024 |
| FY2020 | Dec 31, 2020 | ($32.13M) | Mar 4, 2021 |
| FY2020 | Sep 30, 2020 | ($21.78M) | Mar 4, 2021 |
| FY2020 | Jun 30, 2020 | ($20.09M) | Mar 4, 2021 |
| FY2020 | Mar 31, 2020 | ($18.38M) | Mar 4, 2021 |
| FY2020 | Dec 31, 2019 | ($15.64M) | Mar 4, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($256.03M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($344.18M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | ($362.25M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | ($351.30M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($330.28M) | Mar 19, 2024 |
| FY2023 | Mar 31, 2021 | ($86.26M) | Mar 19, 2024 |
| FY2020 | Dec 31, 2020 | ($30.89M) | Mar 4, 2021 |
| FY2020 | Sep 30, 2020 | ($21.93M) | Mar 4, 2021 |
| FY2020 | Jun 30, 2020 | ($20.23M) | Mar 4, 2021 |
| FY2020 | Mar 31, 2020 | ($18.59M) | Mar 4, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $190.14M | Mar 3, 2025 |
| FY2024 | Dec 31, 2023 | $232.37M | Mar 3, 2025 |
| FY2024 | Dec 31, 2022 | $248.15M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $195.96M | Mar 19, 2024 |
| FY2023 | Mar 31, 2021 | $41.13M | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | $139.51M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $112.00M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $55.72M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $42.04M | Mar 25, 2020 |
| FY2018 | Dec 31, 2016 | $29.15M | Mar 13, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $168.78M | Mar 3, 2025 |
| FY2024 | Dec 31, 2023 | $129.62M | Mar 3, 2025 |
| FY2024 | Dec 31, 2022 | $102.71M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $135.26M | Mar 19, 2024 |
| FY2023 | Mar 31, 2021 | $45.28M | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | $71.32M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $46.46M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $42.72M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $57.12M | Mar 25, 2020 |
| FY2018 | Dec 31, 2016 | $95.39M | Mar 13, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($304.94M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($391.24M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | ($366.76M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | ($337.51M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($274.42M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | ($171.72M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($152.11M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($63.38M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | ($48.78M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2016 | ($38.59M) | Mar 13, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.85M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $6.89M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $30.58M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $78.16M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $33.56M | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | $1.67M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $4.29M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $13.10M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $34.82M | Mar 25, 2020 |
| FY2018 | Dec 31, 2016 | $6.56M | Mar 13, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $501.90M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $382.93M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $504.45M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $362.36M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $468.91M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $221.38M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $143.12M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $181.95M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $250.44M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $317.50M | Mar 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.00B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $871.06M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $1.09B | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $812.18M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $712.82M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $339.87M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $22.44M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $35.94M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $31.60M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $24.08M | Mar 12, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($500.47M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($489.10M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | ($586.99M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($447.33M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($242.17M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($119.81M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $120.68M | Mar 4, 2021 |
| FY2020 | Dec 31, 2018 | $146.01M | Mar 4, 2021 |
| FY2020 | Dec 31, 2017 | $218.84M | Mar 4, 2021 |
| FY2019 | Dec 31, 2016 | $293.42M | Mar 25, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $910.0K | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $910.0K | Feb 23, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.73B) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($3.38B) | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | ($2.96B) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($2.38B) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($1.96B) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($1.62B) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($662.19M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($594.98M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($498.71M) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($387.06M) | Mar 12, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.33M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $143.43M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $265.45M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $104.64M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $181.10M | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | $34.92M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $75.80M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $16.82M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $23.87M | Mar 25, 2020 |
| FY2018 | Dec 31, 2016 | $8.08M | Mar 13, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.01B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | 852.90M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | 670.87M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 421.57M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 397.83M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 382.24M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 98.46M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | 79.09M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | 79.02M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | 81.98M | Mar 12, 2018 |